Immuron Ltd — Investor Presentation 2014

Jul 20, 2014

==> picture [192 x 42] intentionally omitted <==

Immuron CEO Presents at 2014 Bioshares Biotech Summit

Melbourne, Australia - 21 July 2014: Australian biopharmaceutical company Immuron Limited (ASX: IMC) presented at a prestigious Bioshares Biotech Summit in Queenstown, New Zealand on the afternoon of Friday 18[th] July 2014.

The 10[th] Annual Bioshares Biotech Summit is hosted by Australia’s leading independent biotech investment publication Bioshares. The summit joins life science companies from Australia and New Zealand with private and institutional investors from Australasia and the US. It is aptly described as an 'essential biotech investment event' because it brings together executives and investors into the one room for two intense days of presentations and networking.

Immuron’s Chief Executive Office Mr Amos Meltzer’s presentation focused on the Company’s main value proposition being the Phase II NASH clinical trial due to commence last this year.

Following his presentation at the summit Mr Meltzer commented “that the summit was very well attended by approximately 150 persons including a mix of other biotech company management together with a large number of Australian, New Zealand and US fund managers, private investors, brokers and analysts.

It was a fantastic opportunity for Immuron to showcase the upcoming commencement of its fully funded Phase II NASH clinical trial which highlights another step in the unique opportunity Immuron now offers for investors”.

Contacts:

Amos Meltzer, Chief Executive Officer +61 (0)437 587 680

Investor Relations Amanda Loh, Buchan Consulting +61 (0)3 9866 4722

Websites: www.immuron.com and www.travelan.com

About Immuron

Immuron is a biopharmaceutical company focused on oral immunotherapy treatments using dairy-derived antibody products for humans. Immuron’s technology platform products all have a very high safety profile. The company’s current products and product candidates address infectious diseases of the gastrointestinal tract as well as chronic diseases. Immuron has an on-market product, Travelan®, for preventing travellers’ diarrhoea. Immuron also has a phase 2 clinical product candidate for the treatment of inflamed fatty liver disease, known as Non-Alcoholic Steatohepatitis or NASH. Immuron’s main scientific alliances are with Hadassah Medical Center (Israel) and Monash University (Australia).

www.immuron.com

Suite 1, 1233 High Street Armadale, Victoria AUSTRALIA 3143

Phone: + 61 (0)3 9824 5254 Facsimile: + 61 (0)3 9822 7735

ABN: 80 063 114 045

JULY 2014 Amos Meltzer Chief Executive Officer Immuron Limited

==> picture [721 x 541] intentionally omitted <==

----- Start of picture text -----

Diagnosis &
Who am I NASH The Market The Cause
Treatments
----- End of picture text -----

Diagnosis & NASH The Market The Cause Treatments

==> picture [721 x 271] intentionally omitted <==

WHAT IS NASH?

==> picture [443 x 26] intentionally omitted <==

----- Start of picture text -----

Diagnosis &
Who am I NASH The Market The Cause
Treatments
----- End of picture text -----

==> picture [5 x 5] intentionally omitted <==

==> picture [83 x 55] intentionally omitted <==

Cirrhosis:

Liver damage due to formation of scar tissues

Liver Fibrosis:

Scarring of liver tissue commences

NASH/ Inflamed Fatty Liver Inflammation leads to failing liver functions

Lipotoxicity

Non Alcoholic Fatty Liver:

We eat badly and are too sedentary

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

Who am I
----- End of picture text -----

==> picture [263 x 25] intentionally omitted <==

----- Start of picture text -----

Diagnosis &
The Market The Cause
Treatments
----- End of picture text -----

==> picture [721 x 271] intentionally omitted <==

----- Start of picture text -----

….I can live with that.
----- End of picture text -----

==> picture [721 x 271] intentionally omitted <==

HOW BIG IS THE PROBLEM?

==> picture [721 x 541] intentionally omitted <==

----- Start of picture text -----

Diagnosis &
Who am I NASH The Market The Cause
Treatments
Metabolic Syndrome:
The Epidemic of the 21st Century
----- End of picture text -----

==> picture [443 x 26] intentionally omitted <==

----- Start of picture text -----

Diagnosis &
Who am I NASH The Market The Cause
Treatments
----- End of picture text -----

The NASH Epidemic

Currently

NAFL 25% NASH <5%

Global Data, 2013

==> picture [443 x 26] intentionally omitted <==

----- Start of picture text -----

Diagnosis &
Who am I NASH The Market The Cause
Treatments
----- End of picture text -----

The NASH Epidemic

>50yo

NAFL 40% NASH <5%

Deloitte Access Economics, 2013

==> picture [443 x 26] intentionally omitted <==

----- Start of picture text -----

Diagnosis &
Who am I NASH The Market The Cause
Treatments
----- End of picture text -----

The NASH Epidemic

Looking ahead

<16 yo NAFL NASH <5++%

==> picture [721 x 541] intentionally omitted <==

----- Start of picture text -----

Diagnosis &
Who am I NASH The Market The Cause
Treatments
The Market Opportunity
In 2012, 29.1M Americans
(9.3%)had diabetes.
(American Diabetes Association)
By 2025, 25M Americans
will have NASH.
(Centre for Disease Control)
----- End of picture text -----

Diagnosis & Treatments

The Cause

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

Who am I
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

NASH
----- End of picture text -----

==> picture [168 x 165] intentionally omitted <==

(Global Data Forecast, 2011)

==> picture [721 x 271] intentionally omitted <==

WHAT CAUSES NASH?

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

Who am I
----- End of picture text -----

==> picture [177 x 25] intentionally omitted <==

----- Start of picture text -----

NASH The Market
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

Diagnosis &
Treatments
----- End of picture text -----

“ ” Two Hits

1. Oxidative Stress 2. Steatosis

==> picture [77 x 50] intentionally omitted <==

==> picture [721 x 271] intentionally omitted <==

Diagnosis & Treatments

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

Who am I
----- End of picture text -----

==> picture [177 x 25] intentionally omitted <==

----- Start of picture text -----

NASH The Market
----- End of picture text -----

1. Oxidative Stress

2. Steatosis

==> picture [443 x 26] intentionally omitted <==

----- Start of picture text -----

Diagnosis &
Who am I NASH The Market The Cause
Treatments
----- End of picture text -----

==> picture [721 x 431] intentionally omitted <==

----- Start of picture text -----

Part of the Metabolic Syndrome
Inflammation Obesity
FFA
TRG Blood
Insulin Resistance
HDL Pressure
Type II Diabetes
Cardiovascular
disease
----- End of picture text -----

==> picture [443 x 26] intentionally omitted <==

----- Start of picture text -----

Diagnosis &
Who am I NASH The Market The Cause
Treatments
----- End of picture text -----

==> picture [685 x 275] intentionally omitted <==

----- Start of picture text -----

Bacterial
“Leaky Gut”
antigens /
Gut
Endotoxin
Inflammation
Antigen+adjuvant
Strong evidence:
Endotoxin/LPS plays a role in activating M cell
inflammatory pathways associated with NASH. Lamina Propria
Endotoxin drives NASH in a background of fatty Macrophage NKT Perifollicular area Portal
DC Vein
liver.
DC
Interfollicular T cell area
B cell follicule
----- End of picture text -----

==> picture [156 x 61] intentionally omitted <==

----- Start of picture text -----

Systemic
chronic
inflammation
----- End of picture text -----

==> picture [721 x 271] intentionally omitted <==

HOW IS NASH DIAGNOSED?

The Market The Cause

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

Who am I
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

NASH
----- End of picture text -----

↑ ALT, AST, GGT, Dyslipidemia

Rule out other causes of liver disease: alcohol, medications, hepatitis

MRI: incidental sighting of liver steatosis

Metabolic syndrome present? Will Bx change Rx? YES NO BX

YES NO

BX

==> picture [721 x 271] intentionally omitted <==

CURRENT TREATMENTS

Who am I NASH The Market The Cause

==> picture [721 x 271] intentionally omitted <==

==> picture [414 x 27] intentionally omitted <==

----- Start of picture text -----

Diagnosis &
Who am I NASH The Market The Cause
Treatments
----- End of picture text -----

==> picture [721 x 431] intentionally omitted <==

----- Start of picture text -----

Potential treatments previously trialled
Obesity
Antioxidants FFA
TRG Blood
Insulin Resistance
HDL Pressure
Pioglitazones
Metformin Type II Diabetes
No success Cardiovascular
disease
----- End of picture text -----

==> picture [721 x 271] intentionally omitted <==

CURRENT TREATMENTS BEING DEVELOPED

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

Who am I
----- End of picture text -----

==> picture [265 x 27] intentionally omitted <==

----- Start of picture text -----

NASH The Market The Cause
----- End of picture text -----

Research

Preclinical

Phase I

Phase II Phase III

Company

==> picture [721 x 271] intentionally omitted <==

----- Start of picture text -----

Gilead
Intercept
Galectin
Conatus
Galmed
Immuron
Genfit
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

Who am I
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

NASH
----- End of picture text -----

==> picture [175 x 27] intentionally omitted <==

----- Start of picture text -----

The Market The Cause
----- End of picture text -----

Company

Big Small

==> picture [414 x 27] intentionally omitted <==

----- Start of picture text -----

Diagnosis &
Who am I NASH The Market The Cause
Treatments
----- End of picture text -----

Bile Acid

Anti-fibrotic

Anti-Inflammatory + ( )

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

Who am I
----- End of picture text -----

Company

==> picture [265 x 27] intentionally omitted <==

----- Start of picture text -----

NASH The Market The Cause
----- End of picture text -----

Drug

Current Phase

January 9, 2014: Announces results in NASH clinical trials Market cap: $1.5B

CASE STUDY:

Intercept Pharmaceuticals (NASDAQ: ICPT) $1.5B before more than quadrupling overnight on successful NASH trial results

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

Who am I
----- End of picture text -----

==> picture [265 x 27] intentionally omitted <==

----- Start of picture text -----

NASH The Market The Cause
----- End of picture text -----

==> picture [721 x 466] intentionally omitted <==

----- Start of picture text -----

Pathogenesis of NASH
Bacterial
“Leaky Gut”
antigens /
Endotoxin
Antigen+adjuvant
M cell
Lamina Propria
NKT Perifollicular area
Macrophage
DC
DC
Interfollicular T cell area
B cell follicule
Systemic
chronic
inflammation
----- End of picture text -----

==> picture [265 x 27] intentionally omitted <==

----- Start of picture text -----

NASH The Market The Cause
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

Who am I
----- End of picture text -----

==> picture [283 x 178] intentionally omitted <==

==> picture [141 x 89] intentionally omitted <==

Prevents bacterial spread

==> picture [721 x 271] intentionally omitted <==

----- Start of picture text -----

THANK YOU
----- End of picture text -----

By Chief Executive Officer Amos Meltzer amos@immuron.com

==> picture [721 x 541] intentionally omitted <==

----- Start of picture text -----

OVERVIEW TRAVELANWhat is NASH NASH; Causes PIPELINE SUMMARY
Fatty liver Normal liver
----- End of picture text -----